Abstract 1490P
Background
Cancer is a debilitating disease that affects both patients and their caregivers. The diagnosis and treatment of cancer could affect the quality life of the patient and their family. Patients undergoing chemotherapy experience physical and emotional symptoms that affect their quality of life. Some of them experienced difficulty sleeping, depression and poor quality of life. Caregivers of cancer patients may have to cope with a variety of physical, social, and economic problems during the caregiving process. Caregivers experienced caregiver strain while providing care for the patient. The caregiver strain influences the quality of care and thus the quality of life of the patient. Hence, this study aims to determine the health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain.
Methods
A cross sectional analytical study was conducted among cancer patients and their caregiver at the Bataan General Hospital and Medical Center. The EORTC core quality of life questionnaire (QLQ-C30) and modified caregiver strain index (MCSI) questionnaires were administered to assess HRQoL and caregiver strain respectively. Descriptive statistics, Pearson correlation and Spearman rank were performed for analysis of quality-of-life parameters and caregiver strain.
Results
A total of 145 cancer patient-caregiver dyads were included in this study. The median global health status among cancer patients was 75 (66.67 to 91.67) suggesting an optimistic view of overall health and quality of life. The median MCSI score was 19 (14 to 24) indicating a moderate to high level of strain. The relationship between health-related quality of life and caregiver strain showed minimal to no meaningful relationship.
Conclusions
Cancer patients generally exhibit satisfactory to high functioning across physical, role, and cognitive functions. The caregiving role, irrespective of the patient's condition, carries intrinsic challenges. Although the relationship between the HRQoL of patients and caregiver strain was very weak, both are important and functions independently.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10